JP7766026B2 - 自閉症スペクトラム障害の症状を治療する方法 - Google Patents

自閉症スペクトラム障害の症状を治療する方法

Info

Publication number
JP7766026B2
JP7766026B2 JP2022523272A JP2022523272A JP7766026B2 JP 7766026 B2 JP7766026 B2 JP 7766026B2 JP 2022523272 A JP2022523272 A JP 2022523272A JP 2022523272 A JP2022523272 A JP 2022523272A JP 7766026 B2 JP7766026 B2 JP 7766026B2
Authority
JP
Japan
Prior art keywords
points
patient
score
asd
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554090A5 (https=
JP2022554090A (ja
Inventor
ウッド，マイケル
リリー，ジェームズ
Original Assignee
マップライト セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マップライト セラピューティクス，インコーポレイテッド filed Critical マップライト セラピューティクス，インコーポレイテッド
Publication of JP2022554090A publication Critical patent/JP2022554090A/ja
Publication of JP2022554090A5 publication Critical patent/JP2022554090A5/ja
Priority to JP2025180321A priority Critical patent/JP2026031955A/ja
Application granted granted Critical
Publication of JP7766026B2 publication Critical patent/JP7766026B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022523272A 2019-10-23 2020-10-23 自閉症スペクトラム障害の症状を治療する方法 Active JP7766026B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025180321A JP2026031955A (ja) 2019-10-23 2025-10-27 自閉症スペクトラム障害の症状を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962925023P 2019-10-23 2019-10-23
US62/925,023 2019-10-23
US202063011715P 2020-04-17 2020-04-17
US63/011,715 2020-04-17
PCT/US2020/057133 WO2021081376A1 (en) 2019-10-23 2020-10-23 Methods of treating the symptoms of autism spectrum disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025180321A Division JP2026031955A (ja) 2019-10-23 2025-10-27 自閉症スペクトラム障害の症状を治療する方法

Publications (3)

Publication Number Publication Date
JP2022554090A JP2022554090A (ja) 2022-12-28
JP2022554090A5 JP2022554090A5 (https=) 2023-10-31
JP7766026B2 true JP7766026B2 (ja) 2025-11-07

Family

ID=75620321

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523272A Active JP7766026B2 (ja) 2019-10-23 2020-10-23 自閉症スペクトラム障害の症状を治療する方法
JP2025180321A Pending JP2026031955A (ja) 2019-10-23 2025-10-27 自閉症スペクトラム障害の症状を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025180321A Pending JP2026031955A (ja) 2019-10-23 2025-10-27 自閉症スペクトラム障害の症状を治療する方法

Country Status (17)

Country Link
US (1) US20220387396A1 (https=)
EP (2) EP4681714A3 (https=)
JP (2) JP7766026B2 (https=)
KR (1) KR20220122602A (https=)
CN (1) CN114901270A (https=)
AU (1) AU2020370479A1 (https=)
CA (1) CA3158781A1 (https=)
DK (1) DK4048249T3 (https=)
ES (1) ES3056138T3 (https=)
FI (1) FI4048249T3 (https=)
HR (1) HRP20251489T1 (https=)
IL (1) IL292367B1 (https=)
LT (1) LT4048249T (https=)
MX (2) MX2022004910A (https=)
PT (1) PT4048249T (https=)
SI (1) SI4048249T1 (https=)
WO (1) WO2021081376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022079307A1 (en) * 2020-10-16 2022-04-21 Purposeful Ike Compositions and uses thereof
US20240189240A1 (en) * 2021-03-25 2024-06-13 Maplight Therapeutics, Inc. Pharmaceutical compositions comprising zolmitriptan

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236787B2 (en) * 2008-12-09 2012-08-07 Synthonics, Inc. Frequency modulated drug delivery (FMDD)
BR112016027096B1 (pt) * 2014-05-19 2023-04-11 Northeastern University Composições farmacêuticas e compostos de receptores-alvo de serotonina e seus usos
HUE059559T2 (hu) * 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
KR102534545B1 (ko) * 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Pharmacology，2000年，Vol.40, pp.687-700
Nature，2018年，Vol.560，pp.589-594, METHODS, Extended Data
Neuropsychopharmacology，2000年，Vol.22, No.2, pp.163-167

Also Published As

Publication number Publication date
ES3056138T3 (en) 2026-02-18
WO2021081376A1 (en) 2021-04-29
KR20220122602A (ko) 2022-09-02
US20220387396A1 (en) 2022-12-08
EP4681714A3 (en) 2026-04-15
EP4048249A1 (en) 2022-08-31
CN114901270A (zh) 2022-08-12
IL292367B1 (en) 2026-04-01
HRP20251489T1 (hr) 2026-01-02
LT4048249T (lt) 2026-02-10
JP2026031955A (ja) 2026-02-25
DK4048249T3 (da) 2025-12-15
MX2022004910A (es) 2022-08-18
AU2020370479A1 (en) 2022-04-28
EP4681714A2 (en) 2026-01-21
PT4048249T (pt) 2025-12-02
EP4048249B1 (en) 2025-09-03
JP2022554090A (ja) 2022-12-28
EP4048249A4 (en) 2023-12-13
FI4048249T3 (fi) 2025-12-05
SI4048249T1 (sl) 2026-04-30
MX2025008168A (es) 2025-08-01
CA3158781A1 (en) 2021-04-29
IL292367A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
AU2022283769B2 (en) Neuroactive steroids, compositions, and uses thereof
US12377112B2 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
ES2746320T3 (es) Uso de cannabidiol en el tratamiento de trastornos mentales
JP2026031955A (ja) 自閉症スペクトラム障害の症状を治療する方法
US20150359759A1 (en) Compositions and methods for the treatment of pervasive development disorders
JP2019529411A (ja) 不安症およびうつ病の治療のためのプリドピジンの使用
US9254274B2 (en) Method of treating Tourette&#39;S disorder with GABA-aminotransferase inactivators
US20200188358A1 (en) Methods for the treatment of depression
JP2024524679A (ja) アルツハイマー病の処置方法
RU2844953C1 (ru) Способы лечения симптомов расстройства аутистического спектра
IL303006A (en) Use of pyridofidine and analogues for the treatment of Rett syndrome
HK40080588B (en) Methods of treating the symptoms of autism spectrum disorder
HK40080588A (en) Methods of treating the symptoms of autism spectrum disorder
US11213494B2 (en) Compositions and methods for the treatment of pervasive development disorders
AU2016235743A1 (en) Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases
RU2840314C1 (ru) Лечение боязни публичного выступления агонистом альфа-7 никотинового ацетилхолинового рецептора
WO2025145241A1 (en) Treatment of gut-brain interaction disorders
WO2025264845A1 (en) Use of anavex3-71 for medical treatments
CA3257705A1 (en) TREATMENT OF PATIENTS RESISTANT TO ANTIDEPRESSANTS
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Makkonen Childhood autism: aspects of growth factors and monoaminergic transporters in etiopathogenesis
Davies Tuberous sclerosis: from gene to targeted therapy
Bernard et al. Tourette syndrome and the spectrum of neurodevelopmental tic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251027

R150 Certificate of patent or registration of utility model

Ref document number: 7766026

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150